GERMANTOWN, Maryland, November 15, 2021 (GLOBE NEWSWIRE) – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotechnology company that strives to unlock the full potential of cell and gene therapies, has entered into a collaborative agreement (“Agreement”) with the Tel Aviv Sourasky Medical Center to establish a point-of -care (POCare) cell therapy center at Ichilov Hospital, a leading multidisciplinary health facility in Israel.
Under the agreement, the parties plan to conduct collaborative cell-based research projects, initially focused on advancing the clinical development and validation of Orgenesis’ CD19 CAR-T therapies, including products from Orgenesis. exosomes derived from CAR-T, using Orgenesis proprietary T cell culture. and point-of-care processes and systems. The parties also plan to deploy on-site Orgenesis Mobile Processing Units and Laboratories (“OMPUL”) to support joint research and validation activities for advanced cell and gene therapies developed by both Orgenesis and Tel Aviv. Sourasky Medical Center. OMPULs are multi-purpose, mobile, self-contained Good Manufacturing Practices (GMP) facilities designed to dramatically reduce production costs for advanced therapies and accelerate the point-of-care clinical development process.
Vered Caplan, CEO of Orgenesis, said: “It is an honor to collaborate with Tel Aviv Sourasky Medical Center and Professor Irit Avivi, Director of Hematology, to advance the clinical development of cell and gene therapies potentially. revolutionary. This latest collaboration agreement also expands the capacity of our POCare network and provides further validation of the importance of our OMPULs. We remain focused on finding exceptional partners such as the Tel Aviv Sourasky Medical Center to accelerate the development of our broad portfolio of therapies, as well as on the deployment of OMPULs in our network of leading healthcare facilities and partner companies. in the United States, Europe, Asia and the Middle East. “
Professor Eli Sprecher, Deputy Director General of Research, Development and Innovation at Tel Aviv Sourasky Medical Center, said, “We are delighted to partner with Orgenesis to help validate these promising immunotherapies, as well as potentially advance the respective programs in clinical trials. using Orgenesis point-of-service systems and processes. This collaboration, using Orgenesis’ POCare platform, reflects our commitment to help commercialize potentially breakthrough cell therapies in a cost-effective, high-quality and scalable manner.
About Sourasky Medical Center in Tel Aviv
Tel Aviv Sourasky Medical Center (Ichilov Hospital) is the largest acute care facility in Israel, treating approximately 400,000 patients and hosting 1.8 million patient visits per year. A world-class 1,500-bed government university medical center, the Tel Aviv Sourasky Medical Center serves a population of one million people, including residents of the greater Tel Aviv area and visitors to the metropolis. For more information, please visit: https://www.tasmc.org.il/
Orgenesis is a global biotechnology company that strives to unlock the full potential of cell and gene therapy (CGT) in an affordable and accessible format at the point of care. The Orgenesis POCare platform is made up of three enabling elements: a pipeline of POCare Therapeutics which are processed and produced in closed, automated POCare technology systems through collaboration POCare network. Orgenesis Identifies promising new therapies and leverages its POCare platform to provide a fast and globally harmonized path for these therapies to reach and treat large numbers of patients at reduced costs through efficient, scalable production and decentralized. The POCare network brings together patients, doctors, industrial partners, research institutes and hospitals around the world to achieve harmonized and regulated clinical development and production of therapies. www.orgenesis.com
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements that are made in accordance with the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as as amended. These forward-looking statements involve substantial risks and uncertainties and are based on our current expectations, estimates and projections and reflect our beliefs and assumptions based on information available to us as of the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements due to a number of factors, including, but not limited to, our confidence and ability to grow our business. point of view. non-care cell therapy platform, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs based on new technologies, our ability to control key elements related to development and commercialization of therapeutic product candidates with third parties, the timing of clinical trials and studies, the availability of additional data, the results of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage the potential disruptions resulting from the coronavirus epidemic, the sufficiency of working capital to carry out our business plans, the development of our POCare strategy, our differences between entering technology as a therapeutic treatment for diabetes, the technology behind our licensed ATMPs do not not working as expected, our ability to pursue our CGT development projects, either directly or through our JV partnership agreements, and to fulfill our obligations under these agreements, our license agreements with other institutions, our ability to retain key employees , our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading “RISK FACTORS” in point 1A of our annual report on Form 10-K for the year ended December 31 2020, and in our other documents filed with the Securities and Exchange Commission. We assume no obligation to revise or update any forward-looking statement for any reason.
IR contact for Orgenesis:
Crescendo Communications, LLC
Phone. : 212-671-1021